Black Diamond Therapeutics (BDTX) Operating Income (2018 - 2021)
Historic Operating Income for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q4 2021 value amounting to -$26.1 million.
- Black Diamond Therapeutics' Operating Income fell 1249.62% to -$26.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$119.3 million, marking a year-over-year decrease of 7154.23%. This contributed to the annual value of -$126.9 million for FY2021, which is 8236.6% down from last year.
- According to the latest figures from Q4 2021, Black Diamond Therapeutics' Operating Income is -$26.1 million, which was down 1249.62% from -$35.4 million recorded in Q3 2021.
- Black Diamond Therapeutics' Operating Income's 5-year high stood at -$3.0 million during Q4 2018, with a 5-year trough of -$35.4 million in Q3 2021.
- Moreover, its 4-year median value for Operating Income was -$14.0 million (2020), whereas its average is -$16.5 million.
- Its Operating Income has fluctuated over the past 5 years, first tumbled by 23959.29% in 2019, then tumbled by 1249.62% in 2021.
- Quarter analysis of 4 years shows Black Diamond Therapeutics' Operating Income stood at -$3.0 million in 2018, then plummeted by 239.59% to -$10.3 million in 2019, then plummeted by 124.12% to -$23.2 million in 2020, then decreased by 12.5% to -$26.1 million in 2021.
- Its Operating Income was -$26.1 million in Q4 2021, compared to -$35.4 million in Q3 2021 and -$34.7 million in Q2 2021.